Unknown

Dataset Information

0

Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil®) to Tumour Cells Using a Novel TIMP3 Peptide.


ABSTRACT: Doxorubicin is a cytotoxic anthracycline derivative that has been used as a chemotherapeutic in many different forms of human cancer with some success. However, doxorubicin treatment has several side-effects, the most serious of which is cardiomyopathy, that can be fatal. Doxorubicin encapsulation in PEGylated liposomes (Doxil®) has been shown to increase tumour localisation and decrease cardiotoxicity. Conversely, the stability of such liposomes also leads to increased circulation times and accumulation in the skin, resulting in palmar planter erythrodysesthesia, while also limiting release of the drug at the tumour site. Specific targeting of such liposomes to tumour cells has been attempted using various receptor-specific peptides and antibodies. However, targeting a single epitope limits the likely number of tumour targets and increases the risk of tumour resistance through mutation. In this report, Doxil® was coupled to peptide sequence p700 derived from tissue inhibitor of metalloproteinase 3. This Doxil® -P700 complex results in an approximately 100-fold increase in drug uptake, relative to Doxil® alone, by both mouse and human breast cancer cells and immortalised vascular cells resulting in an increase in cytotoxicity. Using p700 to target liposomes in this way may enable specific delivery of doxorubicin or other drugs to a broad range of cancers.

SUBMITTER: Aldughaim MS 

PROVIDER: S-EPMC7795762 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil<sup>®</sup>) to Tumour Cells Using a Novel TIMP3 Peptide.

Aldughaim Mohammed S MS   Muthana Munitta M   Alsaffar Fatimah F   Barker Michael D MD  

Molecules (Basel, Switzerland) 20201228 1


Doxorubicin is a cytotoxic anthracycline derivative that has been used as a chemotherapeutic in many different forms of human cancer with some success. However, doxorubicin treatment has several side-effects, the most serious of which is cardiomyopathy, that can be fatal. Doxorubicin encapsulation in PEGylated liposomes (Doxil<sup>®</sup>) has been shown to increase tumour localisation and decrease cardiotoxicity. Conversely, the stability of such liposomes also leads to increased circulation ti  ...[more]

Similar Datasets

| S-EPMC7589973 | biostudies-literature
| S-EPMC7835975 | biostudies-literature
| S-EPMC2731020 | biostudies-literature
| S-EPMC6603215 | biostudies-literature
| S-EPMC7798203 | biostudies-literature
| S-EPMC2952486 | biostudies-literature
| S-EPMC3175222 | biostudies-literature
| S-EPMC9609487 | biostudies-literature
| S-EPMC8212994 | biostudies-literature
| S-EPMC6606580 | biostudies-literature